Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

Topp, Max S.; Gokbuget, Nicola; Zugmaier, Gerhard; Klappers, Petra; Stelljes, Matthias; Neumann, Svenja; Viardot, Andreas; Marks, Reinhard; Diedrich, Helmut; Faul, Christoph; Reichle, Albrecht; Horst, Heinz-August; Brueggemann, Monika; Wessiepe, Dorothea; Holland, Chris; Alekar, Shilpa; Mergen, Noemi; Einsele, Hermann; Hoelzer, Dieter; Bargou, Ralf C.

Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

Author:

Topp, Max S.; Gokbuget, Nicola; Zugmaier, Gerhard; Klappers, Petra; Stelljes, Matthias; Neumann, Svenja; Viardot, Andreas; Marks, Reinhard; Diedrich, Helmut; Faul, Christoph; Reichle, Albrecht; Horst, Heinz-August; Brueggemann, Monika; Wessiepe, Dorothea; Holland, Chris; Alekar, Shilpa; Mergen, Noemi; Einsele, Hermann; Hoelzer, Dieter; Bargou, Ralf C.

Tübinger Autor(en):

Faul, Christoph

Published in:

Journal of Clinical Oncology (2014), Bd. 32, H. 36, S. 4134-U363

Verlagsangabe:

Amer Soc Clinical Oncology

Language:

English

Full text:

http://dx.doi.org/10.1200/JCO.2014.56.3247

ISSN:

0732-183X